KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Accumulated Expenses (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Accumulated Expenses for 15 consecutive years, with $161.1 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 4.51% to $161.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $161.1 million through Dec 2025, down 4.51% year-over-year, with the annual reading at $161.1 million for FY2025, 4.51% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $161.1 million at Supernus Pharmaceuticals, up from $108.6 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $173.6 million in Q2 2021, with the low at $72.3 million in Q3 2021.
  • Average Accumulated Expenses over 5 years is $136.9 million, with a median of $148.3 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses surged 119.23% in 2022, then tumbled 50.48% in 2023.
  • Over 5 years, Accumulated Expenses stood at $132.7 million in 2021, then increased by 14.27% to $151.7 million in 2022, then rose by 1.72% to $154.3 million in 2023, then grew by 9.35% to $168.7 million in 2024, then fell by 4.51% to $161.1 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $161.1 million, $108.6 million, and $77.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.